Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 785369, 5 pages
http://dx.doi.org/10.1155/2010/785369
Review Article

PPAR Agonists: Blood Pressure and Edema

Department of Biology, Indiana University-Purdue University Indianapolis, 723 West Michigan Street, SL 358 Indianapolis, IN 46202, USA

Received 26 August 2009; Accepted 23 November 2009

Academic Editor: Tianxin Yang

Copyright © 2010 Bonnie L. Blazer-Yost. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. T. Chetty and A. M. Sharma, “Can PPARγ agonists have a role in the management of obesity-related hypertension?” Vascular Pharmacology, vol. 45, no. 1, pp. 46–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Gurnell, “‘Striking the right balance’ in targeting PPARγ in the metabolic syndrome: novel insights from human genetic studies,” PPAR Research, vol. 2007, Article ID 83593, 14 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Yki-Jarvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003. View at Google Scholar · View at Scopus
  5. J. Karalliedde and R. E. Buckingham, “Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies,” Drug Safety, vol. 30, no. 9, pp. 741–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Karalliedde, R. Buckingham, M. Starkie, D. Lorand, M. Stewart, and G. Viberti, “Effect of various diuretic treatments on rosiglitazone-induced fluid retention,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3482–3490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Blasi, J. Heyen, M. Hemkens, A. McHarg, C. M. Ecelbarger, and S. Tiwari, “Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure and kidney in healthy Sprague-Dawley rats,” PPAR Research, vol. 2009, Article ID 237865, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Google Scholar · View at Scopus
  9. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-? and PPAR-a) reduce myocardial infarct size,” The FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Yasuda, H. Kobayashi, M. Iwasa et al., “Antidiabetic drug pioglitazone protects the heart via activation of PPAR-? receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction,” American Journal of Physiology, vol. 296, no. 5, pp. H1558–H1565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Song, M. A. Knepper, X. Hu, J. G. Verbalis, and C. A. Ecelbarger, “Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 426–433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Barroso, M. Gurnell, V. E. F. Crowley et al., “Dominant negative mutations in human PPAR? associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Kleinhenz, D. J. Kleinhenz, S. You et al., “Disruption of endothelial peroxisome proliferator-activated receptor-? reduces vascular nitric oxide production,” American Journal of Physiology, vol. 297, no. 5, pp. H1647–H1654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Chang, L. Villacorta, J. Zhang et al., “Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-? deletion leads to hypotension,” Circulation, vol. 119, no. 16, pp. 2161–2169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Wang, J. D. Symons, H. Zhang, Z. Jia, F. J. Gonzalez, and T. Yang, “Distinct functions of vascular endothelial and smooth muscle PPARγ in regulation of blood pressure and vascular tone,” Toxicologic Pathology, vol. 37, no. 1, pp. 21–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Yang and S. Soodvilai, “Renal and vascular mechanisms of thiazolidinedione-induced fluid retention,” PPAR Research, vol. 2008, Article ID 943614, 8 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPAR? stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. B. L. Blazer-Yost and S. I. Helman, “The amiloride-sensitive epithelial Na+ channel: binding sites and channel densities,” American Journal of Physiology, vol. 272, no. 3, pp. C761–C769, 1997. View at Google Scholar · View at Scopus
  21. S. I. Helman, X. Liu, K. Baldwin, B. L. Blazer-Yost, and W. J. Els, “Time-dependent stimulation by aldosterone of blocker-sensitive ENaCs in A6 epithelia,” American Journal of Physiology, vol. 274, no. 4, pp. C947–C957, 1998. View at Google Scholar · View at Scopus
  22. B. L. Blazer-Yost, X. Liu, and S. I. Helman, “Hormonal regulation of eNaCs: insulin and aldosterone,” American Journal of Physiology, vol. 274, no. 5, pp. C1373–C1379, 1998. View at Google Scholar · View at Scopus
  23. B. L. Blazer-Yost, M. A. Esterman, and C. J. Vlahos, “Insulin-stimulated trafficking of ENaC in renal cells requires PI 3-kinase activity,” American Journal of Physiology, vol. 284, no. 6, pp. C1645–C1653, 2003. View at Google Scholar · View at Scopus
  24. W. J. Els and S. I. Helman, “Regulation of epithelial sodium channel densities by vasopressin signalling,” Cellular Signalling, vol. 1, no. 6, pp. 533–539, 1989. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Chen, B. Yang, J. A. McNulty et al., “GI262570, a peroxisome proliferator-activated receptor ? agonist, changes electrolytes and water reabsorption from the distal nephron in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 2, pp. 718–725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Hong, A. Lockhart, B. Davis et al., “PPAR? activation enhances cell surface ENaCa via up-regulation of SGK1 in human collecting duct cells,” The FASEB Journal, vol. 17, no. 13, pp. 1966–1968, 2003. View at Publisher · View at Google Scholar
  27. C. J. Faletti, N. Perrotti, S. I. Taylor, and B. L. Blazer-Yost, “sgk: an essential convergence point for peptide and steroid hormone regulation of ENaC-mediated Na+ transport,” American Journal of Physiology, vol. 282, no. 3, pp. C494–C500, 2002. View at Google Scholar · View at Scopus
  28. N. Perrotti, R. A. He, S. A. Phillips, C. R. Haft, and S. I. Taylor, “Activation of serum- and glucocorticoid-induced protein kinase (Sgk) by cyclic AMP and insulin,” Journal of Biological Chemistry, vol. 276, no. 12, pp. 9406–9412, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Nofziger, L. Chen, M. A. Shane, C. D. Smith, K. K. Brown, and B. L. Blazer-Yost, “PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel,” Pflugers Archiv European Journal of Physiology, vol. 451, no. 3, pp. 445–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Zanchi, A. Chiolero, M. Maillard, J. Nussberger, H.-R. Brunner, and M. Burnier, “Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1140–1145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. R. A. Shimkets, D. G. Warnock, C. M. Bositis et al., “Liddle's syndrome: heritable human hypertension caused by mutations in the ß subunit of the epithelial sodium channel,” Cell, vol. 79, no. 3, pp. 407–414, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Hansson, L. Schild, Y. Lu et al., “A de novo missense mutation of the ß subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11495–11499, 1995. View at Google Scholar · View at Scopus
  33. S. S. Chang, S. Grunder, A. Hanukoglu et al., “Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1,” Nature Genetics, vol. 12, no. 3, pp. 248–253, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Vallon, E. Hummler, T. Rieg et al., “Thiazolidinedione-induced fluid retention is independent of collecting duct aENaC activity,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 721–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Vandewalle, “Expression and function of CLC and cystic fibrosis transmembrane conductance regulator chloride channels in renal epithelial tubule cells: pathophysiological implications,” Chang Gung Medical Journal, vol. 30, no. 1, pp. 17–25, 2007. View at Google Scholar · View at Scopus
  36. B. K. Krämer, T. Bergler, B. Stoelcker, and S. Waldegger, “Mechanisms of disease: the kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance,” Nature Clinical Practice Nephrology, vol. 4, no. 1, pp. 38–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Jeck, S. Waldegger, A. Lampert et al., “Activating mutation of the renal epithelial chloride channel ClC-Kb, predisposing to hypertension,” Hypertension, vol. 43, no. 6, pp. 1175–1181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Jeck, P. Waldegger, J. Doroszewicz, H. Seyberth, and S. Waldegger, “A common sequence variation of the CLCNKB gene strongly activates ClC-Kb chloride channel activity,” Kidney International, vol. 65, no. 1, pp. 190–197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. M. A. Shane, C. Nofziger, and B. L. Blazer-Yost, “Hormonal regulation of the epithelial Na+ channel: from amphibians to mammals,” General and Comparative Endocrinology, vol. 147, no. 1, pp. 85–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Nofziger, K. K. Brown, C. D. Smith et al., “PPAR? agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line,” American Journal of Physiology, vol. 297, no. 1, pp. F55–F62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. P. J. Bajwa, J. W. Lee, D. S. Straus, and C. Lytle, “Activation of PPARγ by rosiglitazone attenuates intestinal CI secretion,” American Journal of Physiology, vol. 297, no. 1, pp. G82–G89, 2009. View at Publisher · View at Google Scholar · View at Scopus